Skip to main content


Latest articles

15-06-2019 | Rheumatology | News | Article

Ixekizumab tops adalimumab in head-to-head PsA trial

Findings from the SPIRIT-H2H trial, presented at the EULAR 2019 congress in Madrid, Spain, have demonstrated superior efficacy of ixekizumab versus adalimumab among patients with psoriatic arthritis.

14-06-2019 | Rheumatology | News | Article

BE AGILE: Bimekizumab shows promise for ankylosing spondylitis

Bimekizumab may offer a new therapeutic option for patients with ankylosing spondylitis, findings from the BE AGILE study indicate.

14-06-2019 | Rheumatology | News | Article

Safety profile of nintedanib similar in SSc–ILD, IPF

Nintedanib’s safety and tolerability profile is similar in patients with systemic sclerosis-associated interstitial lung disease and those with idiopathic pulmonary fibrosis, according to a comparison of data from the SENSCIS and INPULSIS trials.

14-06-2019 | Rheumatology | News | Article

Bimekizumab shows dual efficacy in patients with psoriatic arthritis

Research shows that patients with psoriatic arthritis gain substantial improvements in both musculoskeletal and skin symptoms with bimekizumab, highlighting the benefits of its ability to neutralize both interleukin-17A and 17F.

14-06-2019 | Rheumatology | News | Article

Pirfenidone disappoints in SSc–ILD trial

Randomized trial findings presented at the EULAR 2019 congress in Madrid, Spain, suggest that pirfenidone does not stabilize or improve lung function in patients with systemic sclerosis-associated interstitial lung disease.

14-06-2019 | Rheumatology | News | Article

Glucocorticoid tapering recommended for RA patients responding to tocilizumab

Rheumatoid arthritis patients who achieve low disease activity with tocilizumab and low-dose glucocorticoids should be considered for glucocorticoid tapering, suggests research presented at the EULAR 2019 congress in Madrid, Spain.

14-06-2019 | Rheumatology | News | Article

Similar JIA outcomes with switch to second TNF inhibitor vs alternative biologic

Juvenile idiopathic arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapy have similar outcomes regardless of whether they switch to a second agent from the same class or an alternative biologic, research suggests.

13-06-2019 | Rheumatology | News | Article

Positive results for fenebrutinib in patients with biologic DMARD refractory RA

Fenebrutinib has shown efficacy for reducing rheumatoid arthritis activity in patients with an inadequate response to either methotrexate or tumor necrosis factor inhibitors, phase II study findings show.

13-06-2019 | Rheumatology | News | Article

Support for filgotinib use in RA patients with inadequate response to methotrexate

Findings from the phase III FINCH 1 trial suggest that use of the selective Janus kinase 1 inhibitor filgotinib may be beneficial for patients with rheumatoid arthritis and a previous inadequate response to methotrexate.

13-06-2019 | Rheumatology | News | Article

Upadacitinib and adalimumab switching beneficial in refractory RA

Patients with rheumatoid arthritis who initially fail to respond to either the Janus kinase inhibitor upadacitinib or the tumor necrosis factor inhibitor adalimumab can benefit from switching to the alternative drug, post-hoc analysis of the SELECT-COMPARE study suggests.

13-06-2019 | Rheumatology | News | Article

Further support for tocilizumab use in giant cell arteritis

More than a third of patients with giant cell arteritis remission who discontinue tocilizumab treatment after 1 year remain in clinical remission for a further 2 years, suggest follow-up results from the GiACTA trial.

12-06-2019 | Rheumatology | News | Article

Tildrakizumab shows promise for PsA

Phase IIb trial results reported at the EULAR 2019 congress in Madrid, Spain, suggest that tildrakizumab may be a promising treatment option for people with psoriatic arthritis.

10-06-2019 | Rheumatology | Highlight | Article

European recommendations for the diagnosis of gout issued

EULAR has issued eight updated evidence-based recommendations to guide the diagnosis of gout.

07-06-2019 | Rheumatology | News | Article

Predictors of sustained remission/LDA in anti-TNF-treated RA patients identified

Sustained remission and low disease activity remain uncommon in patients with rheumatoid arthritis receiving anti-tumor necrosis factor therapy but can be predicted by several factors, shows an analysis published in Rheumatology.

07-06-2019 | Rheumatology | News | Article

Integrated analysis supports safety profile of abatacept in RA

A pooled analysis of data from nine randomized placebo-controlled trials suggests that abatacept has a favorable safety profile among patients with rheumatoid arthritis.

06-06-2019 | Rheumatology | News | Article

Atherosclerotic plaque burden may aid CV risk prediction in psoriatic disease

Increased atherosclerotic plaque burden, as estimated by carotid ultrasound, is associated with an increased risk for cardiovascular events in patients with psoriatic disease, Canadian researchers report.

04-06-2019 | Rheumatology | News | Article

Support for TNF inhibitor dose reduction in RA patients with low disease activity

Dose reduction of tumor necrosis factor (TNF) inhibitors may be an appropriate strategy for rheumatoid arthritis patients who achieve low disease activity while receiving full doses of the agents, report the authors of a Cochrane systematic review.

03-06-2019 | Rheumatology | News | Article

IL-6 receptor inhibition may induce bone erosion repair in RA

Patients with early rheumatoid arthritis who are treated with the interleukin-6 receptor inhibitor tocilizumab experience more pronounced repair of bone erosions than those given adalimumab plus methotrexate, indicate findings from the REBONE study.

31-05-2019 | Rheumatology | News | Article

Metformin may slow knee OA progression in people with obesity

Metformin use may protect against knee cartilage damage in obese people with knee osteoarthritis, suggests an analysis of Osteoarthritis Initiative participants.

30-05-2019 | Rheumatology | News

FDA approves first diagnostic test for joint replacement infections

The US FDA has approved a diagnostic test to aid detection of infections in the synovial fluid surrounding prosthetic joints in patients being considered for revision surgery.

Image Credits